Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Lenograstim is a recombinant glycosylated human granulocyte colony-stimulating factor (rHuG-CSF) which principally regulates the formation and function of neutrophils. Like other colony-stimulating factors (CSFs), lenograstim has been developed for the prevention and treatment of iatrogenic and disease-related neutropenic conditions.
In phase III clinical studies, prophylactic administration of lenograstim shortened the duration of chemotherapy-induced neutropenia in patients with nonmyelogenous cancers who received standard-dose chemotherapy or myeloablative regimens followed by bone marrow transplantation (BMT). A decrease in the incidence of infection after standard regimens and fewer days with infectious and febrile neutropenic episodes during recovery from BMT occurred con-comitantly with the amelioration of neutropenia. In each setting, the decrease in morbidity was associated with shorter hospitalisation times and reduced administration of parenteral antibacterial agents. As with another rHuG-CSF, filgrastim, bone pain (non-serious) was the most common adverse reaction to lenograstim therapy. This occurred in 13% of lenograstim recipients and 5% of placebo recipients treated for chemotherapy-induced neutropenia with standard regimens.
Lenograstim may facilitate dose optimisation and permit limited dose intensification of standard chemotherapy. Furthermore, the drug, used alone or in combination with chemotherapy, is effective in mobilising peripheral blood progenitor cells (PBPCs) for subsequent reinfusion. The latter is a promising technique which may supplement or ultimately replace BMT for stem cell rescue after myeloablative chemotherapy. However, it has yet to be established whether the dose intensification achievable with lenograstim and/or stem cell rescue has a material effect on relapse-free and survival times.
Preliminary data suggest that lenograstim is effective in increasing the neutrophil count in patients with severe chronic neutropenia (Kostmann’s syndrome), as well as patients with AIDS or AIDS-related complex with zidovudine-induced neutropenia.
Thus, lenograstim, like other CSFs, is a valuable adjunct to cytotoxic chemotherapy for the treatment of nonmyelogenous cancers, including myeloablative regimens followed by stem cell rescue with BMT and/or PBPC infusion. Future clinical experience is likely to confirm the usefulness of the drug in the management of disease-related neutropenia, myeloid disorders and neutropenia in patients with AIDS.
Lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor; rHuG-CSF) is a haematopoietic growth factor (HGF) which acts primarily to stimulate proliferation and differentiation of committed progenitor cells of the granulocyte-neutrophil lineage into functionally mature neutrophils. The mean absolute neutrophil count (ANC) in 30 non-neutropenic patients with cancer exceeded 20 × 109/L after administration of lenograstim ≥2 μg/kg/day for 5 days. Moreover, lenograstim therapy corrected previously defective neutrophil function in this particular patient population. The effect of the drug on other mature haematopoietic cell types appears to be without clinical significance.
Lenograstim increases the number of peripheral blood progenitor cells (PBPCs). Preliminary data suggest that mobilisation of PBPCs is particularly successful if lenograstim is given to enhance chemotherapy-induced progenitor cell rebound. However, following the demonstration of stimulation of leukaemic blast cells by other HGFs in vitro, concerns persist over its possible occurrence in vivo.
The pharmacokinetics of lenograstim have been evaluated in patients with cancer and in healthy volunteers. Peak plasma concentrations of lenograstim were reached within 4 to 8 hours after subcutaneous administration. Bioavailability of this route decreased with increasing dosages and was 30% following the recommended daily dose of 5 μg/kg. Peak plasma concentrations of lenograstim administered subcutaneously increased in a dose-proportional manner with multiple-dose administration over 5 days but decreased in a time-dependent fashion between the first and last days at a particular dose. A similar time-dependent decline has been noted after intravenous administration of the drug. The elimination half-life of lenograstim ranged from 3 to 6 hours, although the mechanism by which the drug is metabolised and excreted is unknown.
Lenograstim is a useful adjunct to chemotherapy for the treatment of non-myelogenous malignancies, including myeloablative chemotherapy followed by bone marrow transplantation (BMT). Clinical benefit has been measured in terms of a reduction in morbidity and use of hospital resources in well-designed clinical trials. The effect of the drug on mortality arising from infection has yet to be conclusively determined.
In phase III studies enrolling 120 patients with inflammatory breast cancer or 162 patients with non-Hodgkin’s lymphoma (NHL), each receiving up to 4 cycles of standard-dose chemotherapy, subcutaneous administration of lenograstim 5 μg/kg/day for up to 10 days significantly shortened the duration of neutropenia (ANC <1 × 109/L) during all 4 cycles. There were significantly fewer culture-confirmed infections and a trend towards a reduction in all infections across all chemotherapy cycles in both studies. This was associated with significant reductions in the duration of hospitalisation and in the duration of parenteral antibacterial use.
Lenograstim facilitated dose optimisation, allowing greater delivery of chemotherapy according to the planned dose and schedule, in patients with NHL. The relative dose intensity for lenograstim recipients was significantly greater than that for placebo recipients (93 vs 80%). Furthermore, preliminary evidence from several studies has indicated that the drug permits limited dose intensification of standard regimens. A study in patients with small cell lung cancer (SCLC) undergoing chemotherapy has shown a trend towards a greater long term survival of lenograstim recipients. However, it remains to be conclusively determined whether the modest increase in relative dose intensity or achievable level of dose intensification with lenograstim has a material effect on relapse-free and survival times in patients with chemosensitive tumours.
In a phase III study of 315 patients undergoing BMT, intravenous administration of lenograstim 5 μg/kg/day for up to 28 days did not decrease the overall incidence of infection compared with placebo (93% in both groups), although the median durations of episodes of culture-confirmed infection and febrile neutropenia were significantly shortened (by 3 and 2 days, respectively). Concomitant with this decrease in morbidity were significant reductions in the median number of days of hospitalisation (by 14%), parenteral antibacterial use (by 21%) and parenteral nutrition requirements (by 33%).
Short term treatment with lenograstim (5 μg/kg/day) was usually effective in increasing neutrophil counts in patients with various refractory anaemias or aplastic anaemia, provided the initial count exceeded 0.1 × 109/L. In a large-scale phase III study in 173 elderly patients with acute myeloid leukaemia, lenograstim therapy was associated with a significant increase in the proportion of patients who experienced a complete response to chemotherapy (70 vs 47% for placebo), but overall survival rates were unaltered. However, lenograstim appeared to have no effect on blast cell proliferation. In another study (n = 121), neutrophil recovery was greater in the lenograstim group and the incidence of fever, febrile neutropenia and use of antibacterial agents were reduced. Blast regrowth >5% occurred in 3 lenograstim recipients and 1 placebo recipient. Pending the availability of further clinical data, lenograstim should be used with caution in pre-malignant and malignant myeloid conditions, and should be accompanied by regular monitoring of leucocyte counts.
Data from 2 randomised studies addressing the use of lenograstim as an adjunct to chemotherapy for acute lymphoblastic leukaemia have shown that neutrophil recovery was enhanced, and there was a trend towards fewer infections and reduced use of antibacterial agents in the larger study (n = 73). However, there was no significant effect on the pattern of infection or antibacterial use in either study.
Preliminary findings suggest that lenograstim is effective in increasing neutrophil counts and decreasing symptoms in patients with severe chronic neutropenias, including congenital, cyclic and idiopathic neutropenias. The drug also increased neutrophil counts in 11 of 12 patients with AIDS or AIDS-related complex with zidovudine-induced neutropenia. The clinical status of a small number of patients with glycogen storage disease (type 1b) who had experienced severe and/or recurrent infections also improved after lenograstim therapy.
Preliminary pharmacoeconomic analyses have been performed on 3 phase III randomised trials in patients with inflammatory breast cancer, NHL and SCLC, and 1 trial involving autologous BMT recipients. At the time of the studies, the use of lenograstim reduced the overall costs of care in 3 of these studies, but increased total health care costs in patients with SCLC because lenograstim recipients were able to receive more chemotherapy than placebo recipients. However, several costs, both direct and indirect, were not included in these analyses.
Available data suggest that lenograstim is generally well tolerated, particularly in the setting of BMT, where no difference has been reported in the overall frequency of adverse clinical or laboratory events compared with placebo. Whether or not lenograstim has an effect on graft-versus-host disease in the setting of allogeneic BMT remains to be firmly established.
Bone pain appears to be the most frequent adverse event related to lenograstim use. In placebo-controlled trials, fewer than 1% of BMT patients reported bone pain (n = 436). However, in patients with chemotherapy-induced neutropenia, the incidence of ‘ non-serious’ bone pain was higher in lenograstim recipients compared with placebo (13 vs 5%; n = 230).
Tolerability data from well-controlled studies addressing the use of lenograstim in disease-related neutropenic conditions are currently unavailable. However, the low prevalence of some of these diseases may preclude such studies. At present there are no data available concerning the long term tolerability of lenograstim.
Dosage and Administration
In Western patients, the recommended dosage of lenograstim is 150 μg/m2/day (equivalent in efficacy to 5 μg/kg/day) administered subcutaneously to those with cancer chemotherapy-induced neutropenia or intravenously to those recovering from bone marrow transplantation. However, in Japanese patients receiving standard-dose chemotherapy, the recommended subcutaneous dosage is lower (2 μg/kg/day). Treatment should be initiated either the day after the final chemotherapy dose or after transplantation. In both instances, therapy should be continued until the post-nadir ANC stabilises within the normal range, or for a maximum of 28 days, whichever occurs first.
The recommended induction dosage to correct and maintain neutrophil counts in Japanese patients with severe chronic neutropenia is 2 μg/kg/day, administered subcutaneously. It is likely that a higher dosage (5 to 20 μg/kg/day) will be required in Western patients.
Normally, a complete blood count should be undertaken twice weekly during treatment, and lenograstim should be discontinued immediately if the post-nadir leococyte count exceeds 50 × 109/L.
As with other HGFs, caution is necessary when administering lenograstim to patients with myelodysplastic syndromes or myeloid leukaemia because of the possibility of the drug promoting progression to malignancy or tumour regrowth.
- Hollingshead LM, Goa KL. Recombinant granulocyte colonystimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991 Aug; 42: 300–30
- Chugai-Rhône-Poulenc. Lenograstim Product Monograph. Paris, France, 1993
- Kubota N, Orita T, Hattori K, et al. Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem 1990; 107: 486–92
- Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. (First of two parts). N Engl J Med 1992 Jul 2; 327: 28–35 CrossRef
- Nissen C, Dalle CV, Moser Y. In vitro comparison of the biological potency of glycosylated versus nonglycosylated rG-CSF. Drug Invest 1994 Jun; 7: 346–52
- Kishita M, Motojima H, Oheda M, et al. Stability of granulocyte colony stimulating factor (rHuG-CSF) in serum. The Clinical Report 1992; 26: 221–4
- Oheda M, Hasegawa M, Hattori K, et al. O-Linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerisation and denaturation allowing it to retain its biological activity. J Biol Chem 1990 July; 265 (20): 11432–5
- Nissen C. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur J Cancer 1994; 30A Suppl. 3: S12–4
- Fossat C, Stoppa AM, Sainty D, et al. In vivo stimulation of neutrophil function by lenograstim (glycosylated rHuG-CSF) in oncohematologic patients: results of a phase-I trial. Stem Cells 1994 May; 12: 322–8 CrossRef
- Stoppa AM, Blaise D, Viens P, et al. Phase I study of in vivo lenograstim (rHuG-CSF) for stem cell collection demonstrates improved neutrophil recovery after autologous bone marrow transplantation. Bone Marrow Transplant 1994 May; 13: 541–7
- Stoppa AM. In vivo benefits of granocyte (lenograstim) treatment: enhanced neutrophil functions and PBPC mobilisation [abstract]. 8th Symposium Molecular Biology of Haematopoiesis, Basel, Switzerland, 9 June, 1993
- Maraninchi D, Stoppa A-M, Stevens LA. A phase I dose-escalation study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor; rHuG-CSF) in non-neutropenic patients before autologous bone marrow transplantation. Chugai-Rhône-Poulenc (Paris, France), 1994 (Data on file)
- Humphreys JM, Rugman FP, Davies JM, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutrophil function in vitro and in vivo following chemotherapy and autologous bone marrow transplantation. J Clin Lab Immunol 1991 Feb; 34: 55–61
- Macey MG, Sangster J, Kelsey SM, et al. Pilot study: effects of G-CSF on neutrophil ex-vivo function post bone marrow transplantation. Clin Lab Haematol 1993; 15 (2): 79–85 CrossRef
- Teshima T, Harada M, Takamatsu Y, et al. Granulocyte colonystimulating factor (G-CSF)-induced mobilization of circulating haemopoietic stem cells. Br J Haematol 1993 Aug; 84: 570–3 CrossRef
- Teshima T, Harada M, Takamatsu Y, et al. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant 1992 Sep; 10: 215–20
- Van-Hoef ME, Baumann I, Lange C, et al. Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy. Ann Oncol 1994 Mar; 5: 217–24
- Yamaguchi M, Hirai K, Morita Y, et al. Hemopoietic growth factors regulate the survival of human basophils in vitro. Int Arch Allergy Immunol 1992; 97: 322–9 CrossRef
- Yamaguchi M, Hirai K, Shoji S, et al. Haematopoietic growth factors induce human basophil migration in vitro. Clin Exp Allergy 1992; 22: 379–84 CrossRef
- Schriber JR, Negrin RS. Use and toxicity of the colony-stimulating factors. Drug Saf 1993 Jun; 8: 457–68 CrossRef
- Souza LM, Boone TC, Gabrilove JL, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232: 61–5 CrossRef
- Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323: 871–7 CrossRef
- Dombret H, Yver A, Chastang C, et al. Increased frequency of complete remission by lenograstim recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration after intensive induction chemotherapy in elderly patients with de novo acute myeloid leukemia (AML). Final results of a randomized multicenter double-blind controlled study [abstract no. 910]. Blood 1994 Nov; 84 (10) Suppl. 1: 231a
- Mirro Jr J, Hurwitz CA, Behm FG, et al. Effects of recombinant human hematopoietic growth factors on leukemic blasts from children with acute myeloblastic or lymphoblastic leukemia. Leukemia 1993 Jul; 7: 1026–33
- Matsuda A. Effects of a recombinant human granulocyte colony-stimulating factor (rG-CSF) on human leukemic cells. J Saitama Med School 1989; 16: 59–64
- Ohno R, Tomonaga M, Ohshima T, et al. A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Int J Hematol 1993 Aug; 58: 73–81
- Ohigashi T, Tachibana M, Tazaki H, et al. Bladder cancer cells express functional receptors for granulocyte-colony stimulating factor. J Urol 1992 Jan; 147: 283–6
- Marty M. The optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: a review. Eur J Cancer 1994; 30A Suppl. 3: S20–5
- Stoppa A-M. Use of lenograstim in the collection and use of PBPC. In: Granulocyte reports, vol. 1 (4), 1993: 16–18. Chester: Adis International Limited
- Houston AC, Stevens LA. An open randomised study of the pharmacokinetics of lenograstim (glycosylated recombinant granulocyte colony-stimulating factor; rHuG-CSF) in healthy male volunteers. Chugai-Rhône-Poulenc (Paris, France), 1994 (Data on file)
- Faulds D, Lewis NJW, Milne RJ. Recombinant granulocyte colony-stimulating factor (rG-CSF). Pharmacoeconomic considerations in chemotherapy-induced neutropenia. Phar-macoEconomics 1992 Apr; 1: 231–49
- Goa K, Bryson H. Recombinant granulocyte-macrophage-colony-stimulating factor (rGM-CSF). An appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplantation. PharmacoEconomics 1994; 5 (1): 56–77 CrossRef
- Muggia FM, Carter SK. Malignant diseases. In: Speight TM, editor. Avery’s drug treatment. Principles and practice of clinical pharmacology and therapeutics. 3rd ed. New Zealand: Adis Press, 1987: 1023–77
- Ota K, Ariyoshi Y, Fukuoka M, et al. Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for lung cancer. Jpn J Cancer Chemother 1990; 17 (1): 65–71
- Oyama A, Ota K, Asano S, et al. A double-blind, cross-over clinical trial of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin’s lymphoma [in Japanese]. Nippon Gan Chiryo Gakkai Shi 1990 Oct 20; 25: 2533–48
- Oyama A, Ota K, Asano S, et al. Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin’s lymphoma [in Japanese]. Nippon Gan Chiryo Gakkai Shi 1990 Aug 20; 25: 1619–34
- Richards M. Choice of dose and duration of treatment with lenograstim [abstract]. 5th International Conference on Malignant Lymphoma Current Status and Prospects, Lugano, Switzerland, 8 June, 1993
- Seymour A-M, de Campos E, Thatcher N, et al. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant granulocyte colony-stimulating factor (rHuG-CSF; lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. Chugai-Rhône-Poulenc (Paris, France), 1994 (Data on file)
- Chevallier B, Chollet P, Merrouche Y, et al. Glycosylated rHuG-CSF (lenograstim) prevents morbidity from FEC-HD chemotherapy in inflammatory breast cancer [abstract no. 137]. Proc Am Soc Clin Oncol 1993; 12: 84
- Roché H, Chevallier B, Chollet P, et al. Lenograstim (rhG-CSF prevents morbidity from FEC-HD chemotherapy for inflammatory breast cancer (IBC) [abstract no. P457]. Ann Oncol 1994; 5 Suppl. 8: 91
- Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim (rHuG-CSF) prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. Chugai-Rhône-Poulenc (Paris, France), 1994 (Data on file)
- Chugai-Rhône-Poulenc. Lenograstim Clinical Reference Book. Paris, France, 1995
- Gisselbrecht C, Lepage E, Haioun B, et al. Lenograstim (glycosylated recombinant human G-CSF) supported chemotherapy optimisation in aggressive non-Hodgkin’s lymphoma (NHL) [abstract no. 1226]. Proc Am Soc Clin Oncol 1993; 12: 363
- Gisselbrecht C, Bastion Y, Haioun C, et al. Placebo-controlled phase III trial of lenograstim (glycosylated recombinant human G-CSF) in aggressive non-Hodgkin’s lymphoma (NHL) [abstract no. 652]. Blood 1994 Nov; 84 (10) Suppl. 1: 167a
- Bronchud M. Can haematopoietic growth factors be used to improve the success of cytotoxic chemotherapy?. Anti Cancer Drugs 1993; 4: 127–39 CrossRef
- Livingston RB. Dose Intensity and high dose therapy. Two different concepts. Cancer 1994; 74 suppl.: 1177–83 CrossRef
- Krakowski I, Bui B, Bonichon F, et al. Phase I–II trials on hematological tolerance and intensification of MAID chemotherapy with rG-CSF in locally advanced or metastatic soft tissue sarcoma patients [abstract]. Ann Oncol 1992 Nov; 3 Suppl. 5: 4
- Théodore C. Conventional MVAC (CMVAC) versus intensified MVAC (IMVAC) chemotherapy with supportive lenograstim treatment in urothelial cancer [abstract]. 18th International Congress on Chemotherapy, Stockholm, Sweden, 30 June, 1993
- Ariyoshi Y. A dose-escalation study of high dose carboplatin (CBDCA) and etoposide (VP-16) with lenograstim support in small cell lung cancer (SCLC) patients [abstract]. 18th International Congress on Chemotherapy, Stockholm, Sweden, 30 June, 1993
- Bui BN, Chevallier B, Chevreau C, et al. Efficacy of lenograstim (rhG-CSF) on hematological tolerance to MAID (Mesna, Adriamycin, Ifosfamide and Dacarbazine) chemotherapy in patients with advanced soft tissue sarcoma, and consequences on treatment-dose intensity. Chugai-Rhône-Poulenc (Paris, France), 1994 (Data on file)
- Ferguson JE, Dodwell DJ, Seymour A-M, et al. High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. Br J Cancer 1993; 67: 825–9 CrossRef
- Takada M, Fukuoka M, Ariyoshi Y, et al. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer. Cancer Chemother Pharmacol 1992; 31: 182–6 CrossRef
- Mori K, Saitoh Y, Tominaga K. Recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small cell lung cancer. Eur J Cancer 1993; 29A (5): 677–80 CrossRef
- Thatcher N, Anderson H, Bleehen NM, et al. The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Eur J Cancer. In press
- Woll PJ, Hodgetts J, Lomax L, et al. Can cytotoxic dose intensity be increased by using granulocyte colony stimulating factor? A randomized controlled trial of lenograstim in small cell lung cancer. J Clin Oncol. In press
- Clift RA, Petersen FB, Buckner CD. Marrow transplantation. In: Moosa AR, Schimpff SC, Robson MC, et al., editors. Comprehensive textbook of oncology. 2nd ed. vol. 1. Baltimore: Williams & Wilkins, 1991: 642–52
- Ariad S, Geffen D. Role of colony-stimulating factors during high dosage chemotherapy. Clin Immunother 1994 Jun; 1: 449–59
- Asano S, Masaoka T, Takaku F. Beneficial effect of recombinant human glycosylated granulocyte colony-stimulating factor in marrow-transplanted patients: results of multicenter phase II–III studies. Transplant Proc 1991 Feb; 23 (1 Pt 2): 1701–3
- Takahashi S, Asano S, Masaoka T, et al. Clinical evaluation of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in autologous bone marrow transplantation [in Japanese]. Rinsho Ketsueki 1991 Mar; 32: 221–6
- Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. (Second of two parts). N Engl J Med 1992 Jul 9; 327: 99–106
- Linch DC, Scarffe H, Proctor S, et al. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993 Apr; 11: 307–11
- Gisselbrecht C, Prentice HG, Bacigalupo A, et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994 Mar 19; 343: 696–700 CrossRef
- Miller LL. Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology (Huntingt) 1993 Oct; 7: 67–78, 81-3 (discussion 83-4, 87-8)
- Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992 Mar 14; 339: 640–4 CrossRef
- Frampton JE, Lee CR, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994 Nov; 48: 731–60 CrossRef
- Peters WP, Rosner G, Ross M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993 Apr 1; 81: 1709–19
- Van Hoef MEHM, Ranson M, Morgenstern GR, et al. Rapid haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cells (PBPC) as sole support collected at a single apheresis. Bone Marrow Transplant 1994; 13: 839–40
- Matsunaga T, Sakamaki S, Kohgo Y, et al. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant 1993 Feb; 11: 103–8
- Pettengell R, Morgenstern GR, Woll PJ, et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993 Dec 15; 82: 3770–7
- Jones HM, Jones SA, Watts MJ. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12: 1693–702
- Linch D. Perspectives of PBPC support in lymphoma [abstract]. 19th Congress of the European Society of Medici Oncology, Lisbon, Portugal, 18–22 November, 1994
- Höglund M, Bengtsson M, Simonsson B, et al. Leukapheresis with peripheral blood progenitor cell (PBPC) harvest in healthy volunteers receiving different doses of lenograstim —evidence of a dose-response effect [abstract no. 1377]. Blood 1994 Nov; 84 (10) Suppl. 1: 348a
- Mittelman M, Lessin LS. Myelodysplasia (preleukaemia). In: Moosa AR et al., editors. Comprehensive textbook of oncology. 2nd ed. Baltimore: Williams & Wilkins, 1991: 1232–44
- Yoshida Y, Hirashima K, Asano S, et al. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 1991 Jul; 78: 378–84 CrossRef
- Yoshida Y, Hirashima K, Asano S, et al. Hematological effect of 14 days treatment of recombinant human granulocyte colony-stimulating factor for neutropenia in myelodysplastic syndromes [in Japanese]. Rinsho Ketsueki 1991 Jul; 32: 743–50
- Asano A, Hirashima K, Yoshida Y, et al. Recombinant human granulocyte colony-stimulating factor therapy for neutropenia in aplastic anemia. Biotherapy 1990; 4 (10): 1644–51
- Bacigalupo A. Antilymphocyte globulin (ALG), cyclosporin (CyA) and rHuG-CSF in patients with acquired severe aplastic anaemia: a pilot study of the EBMT SAA working party and status of an ongoing European Phase III trial [abstract]. 20th Annual Meeting of the European Group for Bone Marrow Transplantation and 10th Meeting of the Nurses Group, Harrogate, UK, 13–17 March, 1994
- Izumi T, Muroi K, Takatoku M-a, et al. Development of acute myeloblastic leukaemia in a case of aplastic anaemia treated with granulocyte colony-stimulating factor. Br J Haematol 1994 Jul; 87: 666–8 CrossRef
- Schiffer CA, Schimpff SC. Acute leukaemia. In: Moosa AR et al., editors. Comprehensive textbook of oncology. 2nd ed. Baltimore: Williams & Wilkins, 1991: 1203–11
- Asano S, and The Japan G-CSF Clinical Study Group. Contributions of glycosylated recombinant human G-CSF to the treatment of acute myeloid leukemias [abstract no. 2302]. Blood 1994 Nov; 84 (10) Suppl. 1: 579a
- Smedmyr B. Lenograstim as supportive treatment in newly diagnosed acute lymphoblastic leukaemia [abstract]. 18th International Congress on Chemotherapy, Stockholm, Sweden, 30 June, 1993
- Donadieu J, Boutard P, Tchernia G, et al. A phase II study of recombinant human granulocyte-colony stimulating factor (rHuG-CSF, lenograstim) in the treatment of agranulocytosis in children. Nouv Rev Fr Hematol 1994; 36: 441–8
- Inoue T, Tani K, Tajiri M, et al. A case report of familial cyclic neutropenia. Tohoku J Exp Med 1992; 167: 107–13 CrossRef
- Hanada T, Ono I, Nagasawa T. Childhood cyclic neutropenia treated with recombinant human granulocyte colony stimulating factor. Br J Haematol 1990; 65: 135–7 CrossRef
- Tsunogake S, Nagashima S, Maekawa R, et al. Myeloid progenitor cell growth characteristics and effect of G-CSF in a patient with congenital cyclic neutropenia. Int J Hematol 1991 Jun; 54: 251–6
- Hirashima K, Yoshida Y, Asano S, et al. Clinical effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on various types of neutropenia including cyclic neutropenia. Biotherapy 1991 Oct; 3: 297–307 CrossRef
- Sonada Y, Yashige H, Fujii H, et al. Treatment of idiopathic neutropenia in the elderly with recombinant human granulocyte colony-stimulating factor. Acta Haematol 1991; 85: 146–52 CrossRef
- Vanderwouw PA, van Leeuwen R, van Oers RHJ, et al. Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase-I/II study. Br J Haematol 1991 Jul; 78: 319–24 CrossRef
- Jones EA, Bolyard AA, Dale DC. Quality of life of patients with severe chronic neutropenia receiving long-term treatment with granulocyte colony-stimulating factor. JAMA 1993 Sep 1; 270: 1132–3 CrossRef
- Ueda K, Hanawa Y, Takaku F, et al. The effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on childhood neutropenias [in JAPANESE]. Rinsho Ketsueki 1991 Mar; 32: 212–20
- Griscelli C, Donadieu J. European study of lenograstim in severe congenital agranulocytosis [abstract]. 24th Congress of the International Society of Haematology; 1992 Aug 23–27. London: International Society of Haematology, 1992
- Donadieu J, Badermeunier B, Bertrand Y, et al. Recombinant human G-CSF (lenograstim) for infectious complications in glycogen storage disease type 1b — report of 7 cases. Nouv Rev Fr Hematol 1993 Dec; 35: 529–34
- Lachaux A, Boillot O, Stamm D, et al. Treatment with lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) and orthotopic liver transplantation for glycogen storage disease type Ib. J Pediatr 1993 Dec; 123: 1005–8 CrossRef
- Laurie AS, Gibson FM, Josten KM, et al. Childhood polyclonal T-cell lymphocytosis with neutropenia: effects of antilymphocyte globulin and granulocyte colony stimulating factor in vitro and in vivo. Br J Haematol 1992 Apr; 80: 446–51 CrossRef
- Stoppa AM, Fossat C, Sainty D, et al. In vivo administration of recombinant granulocyte colony stimulating factor corrects acquired neutrophil function deficiency association with chronic graft-versus-host disease. Br J Haematol 1993 Jan; 83: 169–70 CrossRef
- Oster G, Menzin J, Richard D, et al. Overview of the lenograstim pharmacoeconomics programme. Pharmaco-Economics 1994; 6 Suppl. 2: 9–17 CrossRef
- Mapelli V, Graf von der Schulenberg J-M, Laaser U, et al. Economic evaluation of lenograstim (glycosylated rHuG-CSF) in the treatment of inflammatory breast cancer for Germany and Italy. PharmacoEconomics 1994; 6 Suppl. 2: 27–35 CrossRef
- Souêtre E, Qing W. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin’s lymphoma. PharmacoEconomics 1994; 6 Suppl. 2: 36–43 CrossRef
- Drummond M, Davies L. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer. PharmacoEconomics 1994; 6 Suppl. 2: 44–52 CrossRef
- Brice P, Godin S, Libert O, et al. Effect of lenograstim on the cost of autologous bone marrow transplantation. PharmacoEconomics 1995; 7 (3): 238–41 CrossRef
- Menzin J, Oster G, Cour-Chabernaud V, et al. Pharmacoeconomic evaluation of lenograstim. Conclusions and future directions. PharmacoEconomics 1994; 6 Suppl. 2: 53–60
- Hoshina Y, Moriuchi J, Nakamura Y, et al. CD4+ T cell-mediated leukopenia of Felty’s syndrome successfully treated with granulocyte-colony-stimulating-factor and methotrexate. Arthritis Rheum 1994 Feb; 37: 298–9 CrossRef
- Ito T, Miyairi Y, Kuwabara T, et al. Granulocyte-colony stimulating factor corrects granulocytopenia in Felty’s syndrome [letter]. Am J Hematol 1992 Aug; 40: 318–9 CrossRef
- Van Hoef ME, Howell A. Risk of thyroid dysfunction during treatment with G-CSF [letter; comment]. Lancet 1992 Nov 7; 340: 1169–70 CrossRef
- Chugai Pharmaceutical Co. Ltd. Lenograstim prescribing information. Tokyo, Japan, 1993
- Petros WP, Peters WP. Cost implications of haematopoietic growth factors in the BMT setting. Bone Marrow Transplant 1993; 11 Suppl. 2: 36–8
- Hénon PR. Peripheral blood stem cell transplantations: Past, present and future. Stem Cells 1993; 11: 154–72 CrossRef
- Greenberg P, Taylor K, Larson R, et al. Phase III multicenter randomized trial of G-CSF vs observation for myelo-dysplastic syndromes (MDS) [abstract]. Blood 1993; 82 Suppl. 1: 768
- Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993 May 15; 81: 2496–502
Volume 49, Issue 5 , pp 767-793
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors